Noticias

Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?

NASDAQ

Key PointsBristol Myers Squibb has an attractive 4.3% yield, and its P/E is below average for a drug maker.

Leer el informe completo de Veytics

Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.